Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Clinical and Biological Characterization of Post COVID-19 Syndrome

  • Read more about Clinical and Biological Characterization of Post COVID-19 Syndrome

Fluvoxamine for Long COVID-19

  • Read more about Fluvoxamine for Long COVID-19

COVID-19 Antibody and Reinfection Study

  • Read more about COVID-19 Antibody and Reinfection Study

Long Haul COVID Rehabilitation & Recovery Research Program

  • Read more about Long Haul COVID Rehabilitation & Recovery Research Program

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

  • Read more about Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

  • Read more about The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

Long-Covid in Patients Post Rehabilitation Treatment and Reintegration Into Everyday Life

  • Read more about Long-Covid in Patients Post Rehabilitation Treatment and Reintegration Into Everyday Life

Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

  • Read more about Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

  • Read more about Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)

  • Read more about VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 161
  • Page 162
  • Page 163
  • Page 164
  • Current page 165
  • Page 166
  • Page 167
  • Page 168
  • Page 169
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA